Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroo Ishida

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Current Drug Metabolism|April 6, 2019
Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal FailureKenichi Fujita, Natsumi Matsumoto, Hiroo Ishida, et al.
Anticancer Research|January 30, 2026
Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal CancerRiku Yamanaka, Natsumi Matsumoto, Remi Murase, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2023
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancerYukitaka Shibata, Natsumi Matsumoto, Remi Murase, et al.
Japanese Journal of Clinical Oncology|February 28, 2019
Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)Kazuhiro Usui, Takuma Yokoyama, Go Naka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2008
[Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1]Takashi Hirose, Takamichi Hosaka, Masanao Nakashima, et al.
Japanese Journal of Clinical Oncology|March 24, 2022
Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)Go Naka, Takuma Yokoyama, Kazuhiro Usui, et al.
Respirology (Carlton, Vic.)|June 3, 2008
Patient satisfaction with sedation for flexible bronchoscopyTakashi Hirose, Kentaro Okuda, Hiroo Ishida, et al.
Optics Letters|September 18, 2010
Microsecond switching of parametric tunable dispersion compensatorKen Tanizawa, Junya Kurumida, Hiroo Ishida, et al.
BMC Pulmonary Medicine|November 30, 2022
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective studyYuta Nio, Hiroo Ishida, Natsumi Matsumoto, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2019
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38Mariko Iwase, Ken-Ichi Fujita, Yuki Nishimura, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Current Drug Metabolism|April 6, 2019
Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal FailureKenichi Fujita, Natsumi Matsumoto, Hiroo Ishida, et al.
Anticancer Research|January 30, 2026
Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal CancerRiku Yamanaka, Natsumi Matsumoto, Remi Murase, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2023
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancerYukitaka Shibata, Natsumi Matsumoto, Remi Murase, et al.
Japanese Journal of Clinical Oncology|February 28, 2019
Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)Kazuhiro Usui, Takuma Yokoyama, Go Naka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2008
[Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1]Takashi Hirose, Takamichi Hosaka, Masanao Nakashima, et al.
Japanese Journal of Clinical Oncology|March 24, 2022
Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)Go Naka, Takuma Yokoyama, Kazuhiro Usui, et al.
Respirology (Carlton, Vic.)|June 3, 2008
Patient satisfaction with sedation for flexible bronchoscopyTakashi Hirose, Kentaro Okuda, Hiroo Ishida, et al.
Optics Letters|September 18, 2010
Microsecond switching of parametric tunable dispersion compensatorKen Tanizawa, Junya Kurumida, Hiroo Ishida, et al.
BMC Pulmonary Medicine|November 30, 2022
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective studyYuta Nio, Hiroo Ishida, Natsumi Matsumoto, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2019
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38Mariko Iwase, Ken-Ichi Fujita, Yuki Nishimura, et al.
Pageof 8